A layered framework for immune function
Immune responses succeed when tissue surveillance, recruitment, and effector execution remain coordinated. Disease emerges when that architecture breaks down, and therapies often fail when they target the final effector layer without restoring the systems beneath it.
Modern immunology often describes immune responses by their parts: targets, pathways, cytokines, checkpoints, and effector cells. Immune Architecture asks a different question: how are these modules organized spatiotemporally during a normal immune response?
The framework proposes that immunity operates in layers. Foundational tissue surveillance and repair systems support recruitment and coordination, which in turn support adaptive effector function and memory.
This matters because efficient immune responses require ordered propagation across layers. Many therapies address function at the effector layer without restoring the supportive signals and tissue states that underlie durable immune control.
"Immune responses unfold in the same order immunity evolved."
Unlike geology, all immune layers remain active simultaneously. They do not replace each other. They relay — each dependent on the integrity of what lies beneath.
The architecture of immunity is not only evolutionary. It is operational. During an immune response, activation proceeds through the layers in the same order they emerged evolutionarily.
Ancient tissue and cell-intrinsic defense programs react first. More recently evolved systems are recruited later, escalating the response toward adaptive specialization, effector selection, and memory.
Immediate tissue sensing and local immune response. Ancient defense systems detect disruption and initiate rapid protective programs.
Local alarm signals mobilize broader immune participation across tissues, turning local detection into coordinated effector immunity.
Adaptive effector selection and immunological memory refine future responses through specialization, persistence, and recall.
Scroll to deposit each layer — foundational tissue defense first, adaptive execution last. The model highlights why Layer 3 therapies often require intact Layer 1 and Layer 2 support.
Each layer contributes to four core functions. Disease can arise when any one function is overactive, underactive, spatially misplaced, or poorly relayed to the next layer. This makes the framework useful not only as a map of immune evolution, but as a way to interpret pathology and therapeutic opportunity.
Natural killer cell — scanning electron microscopy · NIAID / NIH · Free to use under Unsplash License
Detect and destroy pathogens, damaged cells, and aberrant tissue. The most ancient imperative.
Repair structural damage and restore tissue homeostasis after a response has run its course.
Calibrate the magnitude, specificity, and duration of the response to match the threat.
Terminate active responses and return the system to baseline. Requires successful escalation through higher layers; failure here drives chronic inflammation and fibrotic disease.
Scientific consultant with a background spanning human evolutionary biology, developmental immunology, and immuno-oncology drug development. The layered immunity framework emerged from two decades of work at the intersection of basic immune biology and translational medicine — an attempt to build a unified architecture that is both mechanistically rigorous and clinically actionable.
Previously Senior Director of Immunology at a clinical-stage biotechnology company, where he led the development of novel immunological therapeutics from concept to IND. Now working independently through BCH Consulting, providing target prioritization, disease area strategy, and scientific advisory services to biotech and pharma.
Author of peer-reviewed publications in developmental immunology, translational medicine, and tumor immunology. Named inventor on granted patents in oncology.
Checkpoint inhibitors, targeted therapies, ADCs, and T-cell redirectors can produce profound responses, but many depend on a permissive immune environment. When tumors are immune-excluded, myeloid-dominated, fibrotic, or spatially disorganized, Layer 3 pressure alone may be insufficient.
Immune Architecture reframes these failures as breakdowns in tissue surveillance, recruitment, coordination, or relay. The opportunity is to pair effector therapies with interventions that rebuild the conditions required for durable immunity.
Failures become diagnosable. Cold tumors, chronic inflammation, fibrosis, and autoimmunity can be interpreted as breakdowns in specific layer functions or relay points.
Therapeutic strategy becomes layered. Understanding the cause of immune dysfunction in the context of the layer in which it operates assists the rational selection of disease-relevant therapeutic targets.
Combination logic becomes clearer. Layer 3 therapies may work best when paired with approaches that restore Layer 1 surveillance and Layer 2 recruitment.
The model generates predictions. Spatial biology, immune phenotyping, and tissue-state biomarkers can test whether architectural restoration improves response depth and durability.
Immune Architecture is being developed as a scientific and translational framework for interpreting immune dysfunction, prioritizing targets, and designing more durable therapeutic strategies in oncology, autoimmunity, and chronic inflammatory disease.
BHarman@BCHSci.com